GeneDx Holdings Corp.

NasdaqGS WGS

GeneDx Holdings Corp. Price to Sales Ratio (P/S) on February 06, 2025: 6.39

GeneDx Holdings Corp. Price to Sales Ratio (P/S) is 6.39 on February 06, 2025, a 1,192.76% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

GeneDx Holdings Corp. 52-week high Price to Sales Ratio (P/S) is 10.49 on January 07, 2025, which is 64.11% above the current Price to Sales Ratio (P/S).
GeneDx Holdings Corp. 52-week low Price to Sales Ratio (P/S) is 0.49 on February 07, 2024, which is -92.37% below the current Price to Sales Ratio (P/S).
GeneDx Holdings Corp. average Price to Sales Ratio (P/S) for the last 52 weeks is 4.28.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: WGS

GeneDx Holdings Corp.

CEO	Ms. Katherine A. Stueland
IPO Date	Nov. 4, 2020
Location	United States
Headquarters	North Tower
Employees	1,000
Sector	Healthcare
Industries Telehealth Artificial Intelligence (AI) Autonomous Driving Big Data Biotechnology Clinical Trials Pharmaceuticals Robotics

Description

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Key trends

Past 5 years